The effect of potent antiretroviral therapy and JC virus load in cerebrospinal fluid on clinical outcome of patients with AIDS-associated progressive multifocal leukoencephalopathy

A. De Luca, M. L. Giancola, A. Ammassari, S. Grisetti, M. G. Paglia, M. Gentile, A. Cingolani, R. Murri, G. Liuzzi, A. D'Arminio Monforte, A. Antinori

Research output: Contribution to journalArticle

106 Citations (Scopus)

Abstract

A multicenter analysis of 57 consecutive human immunodeficiency virus-positive patients with progressive multifocal leukoencephalopathy (PML) was performed, to identify correlates of longer survival. JC virus (JCV) DNA was quantified in the cerebrospinal fluid (CSF) by polymerase chain reaction. Two months after therapy, 4% of the patients without highly active antiretroviral therapy (HAART) and 26% with HAART showed neurologic improvement or stability (P = .03), and 8% and 57%, respectively, reached undetectable JCV DNA levels in the CSF (P = .04). One-year probability of survival was .04 without HAART and .46 with HAART. HAART and lack of neurologic progression 2 months after diagnosis were independently associated with longer survival. Among HAART-treated patients, a baseline JCV DNA

Original languageEnglish
Pages (from-to)1077-1083
Number of pages7
JournalJournal of Infectious Diseases
Volume182
Issue number4
DOIs
Publication statusPublished - 2000

Fingerprint

JC Virus
Progressive Multifocal Leukoencephalopathy
Highly Active Antiretroviral Therapy
Cerebrospinal Fluid
Acquired Immunodeficiency Syndrome
Nervous System
Survival
DNA
Therapeutics
HIV
Polymerase Chain Reaction

ASJC Scopus subject areas

  • Immunology
  • Public Health, Environmental and Occupational Health

Cite this

@article{85d7fc555038497489388f4c1873e7a1,
title = "The effect of potent antiretroviral therapy and JC virus load in cerebrospinal fluid on clinical outcome of patients with AIDS-associated progressive multifocal leukoencephalopathy",
abstract = "A multicenter analysis of 57 consecutive human immunodeficiency virus-positive patients with progressive multifocal leukoencephalopathy (PML) was performed, to identify correlates of longer survival. JC virus (JCV) DNA was quantified in the cerebrospinal fluid (CSF) by polymerase chain reaction. Two months after therapy, 4{\%} of the patients without highly active antiretroviral therapy (HAART) and 26{\%} with HAART showed neurologic improvement or stability (P = .03), and 8{\%} and 57{\%}, respectively, reached undetectable JCV DNA levels in the CSF (P = .04). One-year probability of survival was .04 without HAART and .46 with HAART. HAART and lack of neurologic progression 2 months after diagnosis were independently associated with longer survival. Among HAART-treated patients, a baseline JCV DNA",
author = "{De Luca}, A. and Giancola, {M. L.} and A. Ammassari and S. Grisetti and Paglia, {M. G.} and M. Gentile and A. Cingolani and R. Murri and G. Liuzzi and {D'Arminio Monforte}, A. and A. Antinori",
year = "2000",
doi = "10.1086/315817",
language = "English",
volume = "182",
pages = "1077--1083",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - The effect of potent antiretroviral therapy and JC virus load in cerebrospinal fluid on clinical outcome of patients with AIDS-associated progressive multifocal leukoencephalopathy

AU - De Luca, A.

AU - Giancola, M. L.

AU - Ammassari, A.

AU - Grisetti, S.

AU - Paglia, M. G.

AU - Gentile, M.

AU - Cingolani, A.

AU - Murri, R.

AU - Liuzzi, G.

AU - D'Arminio Monforte, A.

AU - Antinori, A.

PY - 2000

Y1 - 2000

N2 - A multicenter analysis of 57 consecutive human immunodeficiency virus-positive patients with progressive multifocal leukoencephalopathy (PML) was performed, to identify correlates of longer survival. JC virus (JCV) DNA was quantified in the cerebrospinal fluid (CSF) by polymerase chain reaction. Two months after therapy, 4% of the patients without highly active antiretroviral therapy (HAART) and 26% with HAART showed neurologic improvement or stability (P = .03), and 8% and 57%, respectively, reached undetectable JCV DNA levels in the CSF (P = .04). One-year probability of survival was .04 without HAART and .46 with HAART. HAART and lack of neurologic progression 2 months after diagnosis were independently associated with longer survival. Among HAART-treated patients, a baseline JCV DNA

AB - A multicenter analysis of 57 consecutive human immunodeficiency virus-positive patients with progressive multifocal leukoencephalopathy (PML) was performed, to identify correlates of longer survival. JC virus (JCV) DNA was quantified in the cerebrospinal fluid (CSF) by polymerase chain reaction. Two months after therapy, 4% of the patients without highly active antiretroviral therapy (HAART) and 26% with HAART showed neurologic improvement or stability (P = .03), and 8% and 57%, respectively, reached undetectable JCV DNA levels in the CSF (P = .04). One-year probability of survival was .04 without HAART and .46 with HAART. HAART and lack of neurologic progression 2 months after diagnosis were independently associated with longer survival. Among HAART-treated patients, a baseline JCV DNA

UR - http://www.scopus.com/inward/record.url?scp=0033800723&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033800723&partnerID=8YFLogxK

U2 - 10.1086/315817

DO - 10.1086/315817

M3 - Article

VL - 182

SP - 1077

EP - 1083

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 4

ER -